Prestige BioPharma has announced that Pharmapark will market its trastuzumab biosimilar in the Russian Federation under the terms of a deal that has just been agreed between the two companies.
The biosimilar rival to Roche’s Herceptin was recently accepted for review by the European Medicines Agency, with Prestige citing “excellent...





